<DOC>
	<DOCNO>NCT01093781</DOCNO>
	<brief_summary>The goal proposal conduct pilot study access antiproteinuric effect aliskiren patient idiopathic membranous nephropathy . Patients treat 3 month aliskiren aim achieve maximum tolerate dose blood pressure ( &gt; 100 &lt; 125 mmHg systolic BP &gt; 75 % reading ) .</brief_summary>
	<brief_title>Aliskiren Patients With Idiopathic Membranous Nephropathy</brief_title>
	<detailed_description>In patient nephrotic syndrome , include patient membranous nephropathy ( MN ) , conservative therapy consist restrict dietary protein intake , control blood pressure ( target blood pressure ≤ 125/75 mmHg ) , hyperlipidemia , edema . Angiotensin-converting enzyme inhibitor ( ACEi ) and/or angiotensin II receptor blocker ( ARB ) effective anti-hypertensive agent reduce proteinuria slow progression renal disease diabetic nondiabetic chronic nephropathy patient reason prefer agent treat hypertension proteinuric renal disease . Recent study suggest renin inhibition aliskiren may renoprotective reduce proteinuria patient type 2 diabetes . Similar observation also report patient membranous nephropathy proteinuria range 1-3 g/24h . These observation suggest aliskiren may powerful antiproteinuric . However , important emphasize , none patient study proteinuria great 3.0 g/24h . Thus , antiproteinuric effect aliskiren patient heavy proteinuria ( e.g . &gt; 4g/24h ) unknown .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<criteria>Inclusion Criteria Idiopathic MN proven diagnostic kidney biopsy . Age ≥18 year ≤ 80 year . Proteinuria measure urinary protein/urinary creatinine &gt; 4.0 spot sample aliquot 24hour urine collection . Estimated GFR ≥ 30 ml/min/1.73m^2 use 4 variable Modification Diet Renal Disease ( MDRD ) equation . Exclusion Criteria Age &lt; 18 year . Estimated Glomerular Filtration Rate ( GFR ) &lt; 30 ml/min/1.73m^2 , serum creatinine &gt; 3.0 mg/dl . Patient must prednisone , calcineurin inhibitor mycophenolate mofetil &gt; 1 month alkylating agent &gt; 6 month . Patients presence active infection secondary cause MN ( e.g . hepatitis B , HIV , systemic lupus erythematosus ( SLE ) , medication , malignancy ) . Type 1 2 diabetes mellitus . Patients recent history steroid induce diabetes evidence diabetic nephropathy renal biopsy perform within 6 month entry study eligible enrollment . Pregnancy nurse safety reason . Acute renal vein thrombosis document prior entry renal US CT scan . Previous therapy Aliskiren</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>membranous nephropathy aliskiren proteinuria , glomerulonephritis</keyword>
</DOC>